EGFR and neoplasm: In this line of clinical observation, a lesser proportion of patients harboring wt KRAS tumors are sensitive to EGFR inhibitors15; and a large proportion of the wt KRAS tumor samples in this study (27/36; 75%) did not exhibit sensitivity to cetuximab.